Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatitis C virus (HCV) replicates in the peripheral blood mononuclear cells (PBMCs), leading to the production of type I interferons (IFNs). It is well known that the gene expression profile of PBMC is similar to that of the liver. The present study explored the dynamic gene expression profile of PBMCs collected from HCV-infected patients undergoing direct-acting antiviral (DAA) therapy. Methods: A prospective cohort comprising 27 patients under DAA therapy was formed. Expression level of IFN-β and its downstream interferon-stimulated genes (ISGs) was measured in PBMCs before and after DAA treatment. Furthermore, immunoblotting was performed to identify the signaling molecules involved in the expression of ISGs. Results: The pretreatment expression level of interferon-induced protein 44 (IFI44) and C-X-C motif chemokine ligand 10 (CXCL10) correlated with the pretreatment expression level of IFN-β. After DAA treatment, a significant decrease in the expression levels of IFN-β, IFI44, and CXCL10 was observed in the PBMCs. Furthermore, the pretreatment expression level of IFN-β and ISGs correlated with the level of signal transducer and activator of transcription 1 (STAT1) phosphorylation, and DAA treatment abrogated STAT1 phosphorylation. Conclusions: Pretreatment activation of IFN-β response is rapidly normalized after DAA treatment. The present study suggests that the decreased type I IFN response by the clearance of HCV might contribute to DAA-induced alleviation of extrahepatic manifestation of chronic HCV infection.
Abstract
Background/Aims: Hepatitis C virus (HCV) replicates in the peripheral blood mononuclear cells (PBMCs), leading to the production of type I interferons (IFNs). It is well known that the gene expression profile of PBMC is similar to that of the liver. The present study explored the dynamic gene expression profile of PBMCs collected from HCV-infected patients undergoing direct-acting antiviral (DAA) therapy. Methods: A prospective cohort comprising 27 patients under DAA therapy was formed. Expression level of IFN-β and its downstream interferon-stimulated genes (ISGs) was measured in PBMCs before and after DAA treatment. Furthermore, immunoblotting was performed to identify the signaling molecules involved in the expression of ISGs. Results: The pretreatment expression level of interferon-induced protein 44 (IFI44) and C-X-C motif chemokine ligand 10 (CXCL10) correlated with the pretreatment expression level of IFN-β. After DAA treatment, a significant decrease in the expression levels of IFN-β, IFI44, and CXCL10 was observed in the PBMCs. Furthermore, the pretreatment expression level of IFN-β and ISGs correlated with the level of signal transducer and activator of transcription 1 (STAT1) phosphorylation, and DAA treatment abrogated STAT1 phosphorylation. Conclusions: Pretreatment activation of IFN-β response is rapidly normalized after DAA treatment. The present study suggests that the decreased type I IFN response by the clearance of HCV might contribute to DAA-induced alleviation of extrahepatic manifestation of chronic HCV infection.
참고문헌 (34)
- Thrift AP, "Global epidemiology and burden of HCV infection and HCV-related disease", Nat Rev Gastroenterol Hepatol, 14, pp.122~132 (2017)[DOI]
- Shin EC, "Immune responses and immunopathology in acute and chronic viral hepatitis", Nat Rev Immunol, 16, pp.509~523 (2016)[DOI]
- Ramos-Casals M, "Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection", J Hepatol, 66, pp.1282~1299 (2017)[DOI]
- Stark GR, "The JAK-STAT pathway at twenty", Immunity, 36, pp.503~514 (2012)[DOI]
- Borden EC, "Interferons at age 50: past, current and future impact on biomedicine", Nat Rev Drug Discov, 6, pp.975~990 (2007)[DOI]
- Snell LM, "Type I interferon in chronic virus infection and cancer", Trends Immunol, 38, pp.542~557 (2017)[DOI]
- Sung PS, "Interferon response in hepatitis C virus (HCV) infection: lessons from cell culture systems of HCV infection", Int J Mol Sci, 16, pp.23683~23694 (2015)[DOI]
- Snell LM, "New insights into type I interferon and the immunopathogenesis of persistent viral infections", Curr Opin Immunol, 34, pp.91~98 (2015)[DOI]
- Sung PS, "Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness", Proc Natl Acad Sci U S A, 112, pp.10443~10448 (2015)[DOI]
- Sung PS, "IFN-<TEX>${\lambda}4$<", TEX> potently blocks IFN-<TEX>${\alpha}$<, Sci Rep, pp.2017, 7[DOI]
- Ono C, "Characterization of miR-122-independent propagation of HCV", PLoS Pathog, 13, pp.e1006374~ (2017)[DOI]
- Petersen T, "Interferon stimulated gene expression in HIV", HCV coinfected patients treated with nitazoxanide, AIDS Res Hum Retroviruses, pp.2016, 32[DOI]
- Radkowski M, "Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin", J Gen Virol, 95, pp.2004~2009 (2014)[DOI]
- Meissner EG, "Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome", J Clin Invest, 124, pp.3352~3363 (2014)[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)[DOI]
- Rosen HR, ""Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?", Hepatology, 65, pp.341~349 (2017)[DOI]
- Sarrazin C, "Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir", Gastroenterology, 151, pp.501~512 (2016)[DOI]
- Seong YJ, "Activation of human natural killer cells by the soluble form of cellular prion protein", Biochem Biophys Res Commun, 464, pp.512~518 (2015)[DOI]
- Sung PS, "Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells", J Virol, 88, pp.9233~9244 (2014)[DOI]
- Holland PM, "Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase", Proc Natl Acad Sci U S A, 88, pp.7276~7280 (1991)[DOI]
- Sung PS, "CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner", Sci Rep, 7, pp.6387~ (2017)[DOI]
- Park SH, "Immune responses to HCV and other hepatitis viruses", Immunity, 40, pp.13~24 (2014)[DOI]
- Horner SM, "Regulation of hepatic innate immunity by hepatitis C virus", Nat Med, 19, pp.879~888 (2013)[DOI]
- Su AI, "Genomic analysis of the host response to hepatitis C virus infection", Proc Natl Acad Sci U S A, 99, pp.15669~15674 (2002)[DOI]
- Lanford RE, "Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA", Proc Natl Acad Sci U S A, 108, pp.11223~11228 (2011)[DOI]
- Wieland SF, "Stealth and cunning: hepatitis B and hepatitis C viruses", J Virol, 79, pp.9369~9380 (2005)[DOI]
- Dill MT, "Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C", Gastroenterology, 140, pp.1021~1031 (2011)[DOI]
- Sarasin-Filipowicz M, "Interferon signaling and treatment outcome in chronic hepatitis C", Proc Natl Acad Sci U S A, 105, pp.7034~7039 (2008)[DOI]
- Wieland S, "Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver", Hepatology, 59, pp.2121~2130 (2014)[DOI]
- Griesbeck M, "Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals", AIDS, 31, pp.1223~1234 (2017)[DOI]
- van der Meer AJ, "Reversion of disease manifestations after HCV eradication", J Hepatol, 65(1 Suppl), pp.S95~S108 (2016)[DOI]
- Rosenberg BR, "Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients", J Infect Dis (2017)[DOI]
- Sansonno D, "Interleukin 28B gene polymorphisms in hepatitis C virusrelated cryoglobulinemic vasculitis", J Rheumatol, 41, pp.91~98 (2014)[DOI]
- Stattermayer AF, "Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C", J Hepatol, 57, pp.492~498 (2012)[DOI]